COVID-19

Acreage Reports Second Quarter 2024 Financial Results

Commenced Non-Medical Sales in Ohio Market, Expected to Double Revenue in the State by 2025 from ~$50 million in 2023Focused…

1 year ago

Zomedica Announces Second Quarter 2024 Financial Results: Revenue of $6.1 Million; 71% Gross Margin, and $83.0 Million in Liquidity to Support Growth

Diagnostic revenues up 68% year-over-year ANN ARBOR, MI / ACCESSWIRE / August 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica"…

1 year ago

NHI Announces Public Offering Of Common Stock

MURFREESBORO, TN / ACCESSWIRE / August 14, 2024 / National Health Investors, Inc. (NYSE:NHI) (the "Company") announced today that it…

1 year ago

Spero Clinic Offers Hope for Long COVID Patients

Unique treatment program offers promising results for Long COVID patients who are experiencing extreme symptoms related to the virus.FAYETTEVILLE, AR…

1 year ago

Moderna and Coursera Launch Free Course on mRNA Technology

Companies share joint commitment to leveraging technology for STEM educationAccessible education on cutting-edge science and technology represents critical step toward…

1 year ago

Zomedica Continues Global Expansion Through Strategic Partnership with SIRE Veterinario, S.A for Sales Expansion in Central America

SIRE Veterinario, SA Selected as Distribution Partner to Launch Zomedica® Products into Costa Rica ANN ARBOR, MI / ACCESSWIRE /…

1 year ago

Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights

PEMGARDA™ launched commercially in Q2 2024 with $2.3 million of net product revenueNotable acceleration of commercial results in early Q3…

1 year ago

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:…

1 year ago

Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™

Applauds first FDA approval of non-injection-based epinephrine deviceReiterates expected timing for filing of New Drug Application (NDA) for Anaphylm™ (epinephrine)…

1 year ago

Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Expects to report topline results in 2025 from Phase 2a influenza A human challenge study with oral CC-42344, including initial…

1 year ago